Impact of proteogenomic evidence on clinical success

Plasma protein quantitative trait loci (pQTL)-supported target-indication pairs are 4.4 times more likely to progress from Phase I to launch than other genetic evidence in drug development.

• Why it matters: This finding highlights the potential of pQTL data to improve success rates in drug development, addressing the gap in effective biomarkers and target validation.
• What they did: The study analyzed the impact of plasma pQTL on therapeutic hypotheses, comparing their influence to other forms of human genetic evidence across drug development phases.
• The result: pQTL-supported targets show a significantly higher likelihood of advancing through clinical phases, especially within druggable protein families with limited enrichment from other genetic sources, suggesting pQTL's unique value.